Plain-English translation of NCT06091332 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help prevent future bleeding in people who have experienced bleeding from cavernous malformations—abnormal blood vessels in the brainstem of the brain. Researchers want to see if the medication is safe and whether it reduces the risk of dangerous rebleeding during the months and years after the first bleed.
Brainstem cavernous malformations can bleed repeatedly, which is very dangerous and can cause permanent disability. Currently, doctors don't have many proven treatment options to prevent this rebleeding, so this study is testing whether this medication might offer a new way to protect patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take either a higher dose of the medication, a lower dose, or a placebo (a fake pill) by mouth every day for 12 months—you won't know which group you're in. You'll have regular visits with the research team to check your blood levels, monitor for side effects, and have MRI scans of your brain to watch for any changes. The study lasts one year total.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China